{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:54:10Z","timestamp":1787698450711,"version":"build-2784847793"},"reference-count":43,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hepatology Research"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>Prognosis of liver cirrhosis patients is poor when ascites is present and liver function is impaired, but such up\u2010to\u2010date information from a large\u2010scale, real\u2010world setting is limited in Japan. We aimed to investigate the hospital mortality of Japanese liver cirrhosis inpatients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study included data on liver cirrhosis inpatients between January 2011 and September 2018 extracted from an administrative claims database. The outcome was in\u2010hospital mortality. The 1\u2010 and 3\u2010year cumulative survival rates were examined for liver cirrhosis etiology, Child\u2013Pugh classification, or ascites presence\/absence using Kaplan\u2013Meier analysis. The survival up to 1\u00a0year for tolvaptan prescription\/nonprescription was examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We analyzed the data of 57\u00a0769 inpatients. Survival rates did not substantially differ among etiologies, with a better prognosis for alcohol etiology and poorer prognosis for hepatitis C virus. According to the Child\u2013Pugh classification, the 1\u2010 and 3\u2010year survival rates were 90.2% and 75.3% for grade A, 73.5% and 53.9% for grade B, and 41.9% and 28.9% for grade C, respectively. Patients without ascites had a higher survival rate (83.2% and 67.0% at 1 and 3\u00a0years, respectively) than those with ascites (51.9% and 36.3%, respectively). Based on examining matched patients with ascites using a propensity score, prognosis was poor in general but was better at 6\u00a0months (58.1%) or similar at 1\u00a0year (47.1%) in patients prescribed tolvaptan compared to those not prescribed tolvaptan (54.8% and 47.5%, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Poorer prognosis was suggested in inpatients with cirrhosis who had a worse Child\u2013Pugh grade and ascites.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hepr.13635","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T10:35:20Z","timestamp":1615545320000},"page":"682-693","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Real\u2010world hospital mortality of liver cirrhosis inpatients in Japan: a large\u2010scale cohort study using a medical claims database"],"prefix":"10.1111","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5487-3403","authenticated-orcid":false,"given":"Hiroshi","family":"Yatsuhashi","sequence":"first","affiliation":[{"name":"National Hospital Organization, Nagasaki Medical Center  Omura Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Sano","sequence":"additional","affiliation":[{"name":"Medical Affairs Otsuka Pharmaceutical Co., Ltd.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Hirano","sequence":"additional","affiliation":[{"name":"Medical Affairs Otsuka Pharmaceutical Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Shibasaki","sequence":"additional","affiliation":[{"name":"Medical Affairs Otsuka Pharmaceutical Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-019-01645-y"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2957\/kanzo.61.314"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840070124"},{"issue":"2","key":"e_1_2_8_5_1","first-page":"171","article-title":"Frequency of different complications and outcome in patients with cirrhosis liver","volume":"8","author":"Ullah F","year":"2015","journal-title":"KJMS"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.05.004"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","unstructured":"GuevaraM C\u00e1rdenasA UrizJ Gin\u00e8sP.Prognosis of patients with cirrhosis and ascites. In:Gin\u00e8sP ArroyoV Rod\u00e9sJ SchrierRW eds.Ascites and renal dysfunction in liver disease.2nd ed.Oxford:Blackwell Publishing Ltd.2005;260\u201370.","DOI":"10.1002\/9780470987476.ch21"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001056"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.08.007"},{"issue":"3","key":"e_1_2_8_10_1","first-page":"860","article-title":"OPC\u201041061, a highly potent human vasopressin V2\u2010receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats","volume":"287","author":"Yamamura Y","year":"1998","journal-title":"J Pharmacol Exp Therapeut"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-016-1216-y"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14047"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14965"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13337"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14524"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000494438"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12822"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-019-01623-4"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-020-01691-x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12852"},{"issue":"6","key":"e_1_2_8_21_1","first-page":"558","article-title":"Tolvaptan is effective in treating patients with refractory ascites due to cirrhosis","volume":"7","author":"Tahara T","year":"2017","journal-title":"Biomed Rep"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i45.8062"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000501267"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-3840(64)80003-4"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.10.013"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.10.016"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.2957\/kanzo.58.379"},{"key":"e_1_2_8_28_1","volume-title":"Medical data vision"},{"key":"e_1_2_8_29_1","volume-title":"Pharmacoepidemiology & Database Taskforce"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_2_8_32_1","volume-title":"Life prognosis of patients with liver cirrhosis. FY 2014 Ministry of Health, Labour and Welfare Scientific research grant (Comprehensive Research Project on Measures for Persons with Disabilities) Shared research report","author":"Yatsuhashi H"},{"key":"e_1_2_8_33_1","unstructured":"ImaiM IshikawaT OkoshiM et\u00a0al.Status and long\u2010term prognosis of patients with cirrhosis after initial treatment of esophageal varices at our hospital. In:UenoY HiasaY EnomotoH eds.Actual conditions of cirrhosis by cause of liver cirrhosis 2018.Tokyo:Medical Book Publishing;2019:70\u20133."},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14964-1"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50315"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2011.06925.x"},{"issue":"2","key":"e_1_2_8_37_1","first-page":"129","article-title":"Comparative pharmacodynamics of furosemide and muzolimine in cirrhosis. Study on renal sodium and potassium handling and renin\u2010aldosterone axis","volume":"74","author":"Bernardi M","year":"1985","journal-title":"Z Kardiol"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(87)91007-9"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12099"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12098"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300060513480089"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.102764"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.3999\/jscpt.47.21"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-020-01727-2"}],"container-title":["Hepatology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hepr.13635","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hepr.13635","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hepr.13635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T06:47:12Z","timestamp":1693378032000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hepr.13635"}},"subtitle":["Prognosis of liver cirrhosis"],"short-title":[],"issued":{"date-parts":[[2021,3,27]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1111\/hepr.13635"],"URL":"https:\/\/doi.org\/10.1111\/hepr.13635","archive":["Portico"],"relation":{},"ISSN":["1386-6346","1872-034X"],"issn-type":[{"value":"1386-6346","type":"print"},{"value":"1872-034X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,27]]},"assertion":[{"value":"2020-12-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}